Is it safe to perform a contrast‑enhanced computed tomography (CT) scan in a patient receiving peritoneal dialysis?

Contrast CT in Peritoneal Dialysis Patients: Safety Recommendation

Yes, contrast-enhanced CT can be safely performed in patients on peritoneal dialysis if they have no residual renal function. 1111

Key Decision Point: Residual Renal Function

The critical factor determining safety is whether the patient retains any residual kidney function:

• No residual renal function: Contrast CT is safe and can proceed without special precautions regarding nephrotoxicity
• Preserved residual renal function: The risk-benefit ratio must be carefully evaluated, as iodinated contrast poses nephrotoxic risk to remaining kidney function

According to the 2021 ACR Appropriateness Criteria, patients already on hemodialysis or peritoneal dialysis may undergo contrast-enhanced CT if there is no residual renal function 1111. This represents the authoritative guideline position from the American College of Radiology.

Clinical Reasoning

Why This Matters

The concern with iodinated contrast in renal failure patients centers on:

• Contrast-induced acute kidney injury (CI-AKI) in those with remaining function
• Loss of residual renal function, which significantly impacts quality of life and dialysis adequacy in PD patients

Once a patient has no residual function, the nephrotoxic risk becomes irrelevant—there is no remaining kidney function to damage.

Assessing Residual Renal Function

Before proceeding with contrast CT in a PD patient, verify:

• 24-hour urine output (typically <200 mL/day indicates minimal residual function)
• Recent residual GFR measurements if available from PD adequacy testing
• Clinical history of progressive anuria

Important Caveats

Rare Complications Still Possible

While nephrotoxicity is not a concern without residual function, one case report describes contrast-induced encephalopathy (CIE) in a PD patient following intra-arterial contrast administration 2. This patient had multiple risk factors (diabetes, hypertension, chronic heart failure) and developed transient mental confusion and aphasia after carotid angioplasty. This represents an extremely rare complication but highlights that:

• Intra-arterial contrast carries higher risk than intravenous administration
• Patients with multiple vascular risk factors warrant closer monitoring
• CIE should be considered if neurological symptoms develop immediately post-procedure

Technical Considerations for CT Peritoneography

If performing CT peritoneography (contrast instilled into peritoneal cavity), recent evidence confirms:

• Non-ionic iodinated contrast agents (iopamidol, iohexol, iodixanol) are chemically stable when mixed with 1.5% dextrose PD solution 3
• No adverse effects on peritoneal membrane or residual renal function in animal studies 4
• Standard concentration: 50 mL (350 mgI/mL) iohexol per 2L peritoneal dialysate 4

Alternative Imaging Options

If residual renal function is present and must be preserved:

• Ultrasound with contrast: US contrast agents are not nephrotoxic and safe in all stages of kidney disease 11
• Unenhanced CT: Useful for urinary calculi, hydronephrosis, and some retroperitoneal pathology 1
• Unenhanced MRI: Can evaluate obstruction and some morphologic abnormalities, though gadolinium carries nephrogenic systemic fibrosis risk 1

Bottom Line Algorithm

1. Determine residual renal function status (urine output, recent GFR measurements)
2. If no residual function: Proceed with contrast CT safely
3. If residual function present:
   • Evaluate if contrast is absolutely necessary for diagnosis
   • Consider non-contrast alternatives first
   • If contrast essential, use lowest effective dose with adequate hydration
4. For intra-arterial procedures: Monitor closely for rare complications like CIE, especially in patients with multiple vascular risk factors